Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REASON: Anagliptin vs Sitagliptin for LDL-C in T2D
NCT02330406Phase 4Completed
- Sponsor
- IECS
- Start
- Apr 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of anagliptin in type 2 diabetes mellitus (T2DM), sponsored by IECS. Started Apr 2015; status: completed.
02
Drugs
anagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02330406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02330406.